IN THE CLAIMS:

and

- 1. (Currently Amended) A transdermal system consisting of comprising:
- a) a cover layer,
- b) an active-ingredient containing a polymer layer comprising at least one active ingredient,
 - c) an optionally active-ingredient-containing adhesive layer,
 - d) a protective layer, Release Lines

wherein the active ingredient-containing polymer layer comprises water-soluble polymers and the at least one active ingredients are is present in the polymer layer in the form of (an) at least one active ingredient solution(s) or dispersion(s) which are is not miscible with water and wherein the at least one active ingredient is adapted to be delivered in a surge upon the breakdown of the polymer layer.

- 2. (Cancelled).
- 3. (Cancelled).

4 (Previously Amended) A transdermal system according to claim 1, wherein the water-soluble polymer is gelatin.

5. (Previously Amended) A transdermal system according to claim 1, wherein the polymer layer is perforated, so that at least the adhesive layer above the polymer layer can come in to contact with the cover layer and the adhesive layer below the polymer layer.

- 6. (Cancelled).
- 7. (Cancelled).
- 8/(Previously Amended) A transdermal system according to claim 1, wherein the thickness of the adhesive layer below the polymer layer is from 10 to 300 μ m.



9. (Cancelled).

according to claim 1 wherein in a freely selectable order, applying an adhesive layer onto is applied to a protective layer, applying an active ingredient containing a polymer layer comprising at least one active ingredient, optionally having perforations is applied onto the adhesive layer, optionally applying a further adhesive layer is optionally applied above the polymer layer, and applying a cover layer is applied to the top as an uppermost layer.

11. (Previously Amended) A transdermal system according to claim 1, wherein the Bouleshur cover layer comprises one or more water-vapour-impermeable material(s).

12. (Previously Amended) A transdermal system according to claim 1, wherein the adhesive layer is a pressure-sensitive adhesive layer.

13. (Previously Amended) A transdermal system according to claim 1, wherein the adhesive layer comprises a net, a non-woven fabric or a woven fabric.

14. (Currently Amended) A transdermal system according to claim 1, wherein the detachable protective layer is a siliconised plastics film adapted to be detachable.

(Currently Amended) A transdermal system according to claim 1, wherein the <u>at</u> least one active ingredient is testosterone.

16. (Cancelled).

17: (Previously Amended) A transdermal system according to claim 1 wherein the water-soluble polymer is a cellulose ester or derivatives thereof.

18. (Previously Amended) A transdermal system according to claim 1 wherein the water-soluble polymer is a cellulose ether or derivatives thereof.

19. (Currently Amended) A transdermal system according to claim 8, wherein the thickness of the adhesive layer below the polymer layer is from 30 to 100 μ m.



20 (Original) A transdermal system according to claim 11, wherein the water-vapour-impermeable material is polyester.

(Original) A transdermal system according to claim 11, wherein the water-vapour-impermeable material is a polyterephthalic acid ester.

(Previously Amended) A transdermal system according to claim 11, wherein the water-vapour-impermeable material is polypropylene or polyethylene.

23 (Original) A transdermal system according to claim 11, wherein the water-vapour-impermeable material is polyurethane.

D2

24. (Currently Amended) A transdermal system according to claim 11, wherein the water-vapour-impermeable material is a non-woven fabric or a woven fabric.

25. (Cancelled).

Dr

26- (Currently Amended) A transdermal system according to claim 1324, wherein the non-woven fabric or a woven fabric thread or fibre thickness is less than the thickness of the adhesive layers.

27 (Previously Amended) A transdermal system according to claim 14, wherein the detachable protective layer is a silicone paper.

N7

28 (Currently Amended) A transdermal system according to claim 1, wherein the <u>at</u> least one active ingredient is nicotine.

29. (Currently Amended) A transdermal system according to claim 1, wherein the <u>at</u> <u>least one</u> active ingredient is nitroglycerine.

30. (Previously Amended) A method of treating Angina pectoris, nicotine withdrawal or testosterone deficiency symptoms by the administration of a transdermal system according to claim 1.

Original) A transdermal system according to claim 1, wherein the polymer layer is perforated, so that the adhesive layer below the polymer layer can come into contact with the cover layer.



22. (Currently Amended) A transdermal system according to claim 1, wherein the <u>at</u> least one active ingredient is a mixture of at least two components selected from the group consisting of testosterone, nitroglycerine and nicotine.